Table 1.
Patient and tumour characteristics (n = 372)
| Gender, n% | |
| Male | 189, 50.8% |
| Female | 183, 49.2% |
| Age, mean ± SD | 65.7 ± 12.9 |
| Race, n% | |
| Caucasian | 314, 84.4% |
| African American | 49, 13.2% |
| Othera | 9, 2.4% |
| History of prior malignancy, n% | |
| Yes | 54, 14.5% |
| No | 318, 85.5% |
| Known Lynch syndrome, n% | |
| Yes | 7, 1.9% |
| No | 365, 98.1% |
| CEA level at resection, n, mean ± SD | 275, 6.8 ± 21.2 |
| Adjuvant chemotherapy, n% | n = 371 |
| Yes | 105, 28.3% |
| No | 266, 71.7% |
| Location, n% | |
| Right | 227, 61.0% |
| Left | 145, 39.0% |
| Tumour buds, n% | |
| Low | 302, 81.2% |
| Intermediate | 31, 8.3% |
| High | 39, 10.5% |
| Desmoplastic reaction, n% | |
| Immature/myxoid | 67, 18.0% |
| Intermediate | 140, 37.6% |
| Mature | 165, 44.4%% |
| Intra-epithelial tumour-infiltrating lymphocytes, n% | |
| Yes | 130, 35.0% |
| No | 242, 65.1% |
| Tumour grade, n% | |
| Well/moderately differentiated | 294, 79.0% |
| Poorly differentiated | 56, 15.1% |
| Mucinous carcinoma | 22, 5.9% |
| Lymphovascular invasion, n% | |
| Yes | 138, 37.1% |
| No | 234, 62.9% |
| Perineural invasion, n% | |
| Yes | 57, 15.3% |
| No | 315, 84.7% |
| Tumour deposits, n% | |
| Yes | 43, 11.6% |
| No | 329, 88.4% |
| Number of tumour deposits, mean ± SD | 0.39 ± 2.07 |
| Number of involved lymph nodes, mean ± SD | 1.29 ± 2.73 |
| Number of lymph nodes evaluated, mean ± SD | 20.1 ± 8.0 |
| MMR expression, n% | n = 324 |
| Deficient | 67, 20.7% |
| Proficient | 257, 79.3% |
| pT stage, n% | |
| pT1 | 26, 7.0% |
| pT2 | 74, 19.9% |
| pT3 | 224, 60.2% |
| pT4 | 48, 12.9% |
| pN stage, n% | |
| pN0 | 233, 62.6% |
| pN1 | 89, 23.9% |
| pN2 | 50, 13.4% |
| pTNM prognostic group, n% | |
| I | 83, 22.3% |
| II | 150, 40.3% |
| III | 139, 37.4% |
SD, standard deviation; CEA, carcinoembryonic antigen; MMR, mismatch repair; pT, pathological T category; pTNM, pathological tumour–node–metastasis.
a
Asian or Hispanic
Percentages might not total 100% due to rounding